Skip to main content

Table 3 Noncompartmental pharmacokinetic parameters

From: Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

Parameter

MEDI-546

0.1 mg/kg single dose

0.3 mg/kg single dose

1.0 mg/kg single dose

3.0 mg/kg single dose

10.0 mg/kg single dose

20.0 mg/kg single dose

0.3 mg/kg/week multiple dose

1.0 mg/kg/week multiple dose

5.0 mg/kg/week multiple dose

1stdose

4thdose

1stdose

4thdose

1stdose

4thdose

Number of subjects

1

4

4

4

4

4

4

4

4

4

5

3

Cmax, mean (SD), μg/mL

1.97 (NA)

6.69 (1.47)

23.3 (2.22)

72.4 (13.7)

213 (44.0)

394 (83.5)

6.43 (0.470)

6.32 (1.01)

19.1 (7.80)

35.8 (15.5)

87.6 (19.3)

135 (26.5)

AUCa, mean (SD), μg · day/mL

2.45 (NA)

12.4 (4.91)

102 (14.1)

497 (105)

2610 (728)

4870 (1750)

NA

10.7 (2.53)

NA

159 (68.9)

NA

849 (165)

CL, mean (SD), mL/kg/day

40.8 (NA)

27.4 (11.0)

9.94 (1.44)

6.26 (1.43)

4.07 (1.13)

4.67 (2.18)

NA

NA

NA

NA

NA

NA

t1/2, mean (SD), d

0.84 (NA)

1.24 (0.358)

2.96 (0.593)

4.07 (1.23)

7.70 (2.26)

11.8 (2.06)

NA

1.06 (0.174)

NA

4.94 (1.47)

NA

6.28 (0.921)

  1. aAUCinf for single-dose groups and AUC0–7 for multiple-dose groups.
  2. AUCinf area under the serum concentration-time curve from zero to infinity; AUC0–7, AUC from day 0 to day 7 post dose administration; CL, systemic clearance; Cmax, maximum serum concentration; d, days; NA, not available; SD, standard deviation; t1/2, serum elimination half-life.